Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 5/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.52 |
| ▸ | HTR2A | P28223 | 5/20 | 0.52 |
| ▸ | HTR2B | P41595 | 5/20 | 0.52 |
| ▸ | HRH1 | P35367 | 5/20 | 0.52 |
| ▸ | HTR1A | P08908 | 4/20 | 0.52 |
| ▸ | HTR2C | P28335 | 4/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.46 |
| ▸ | DRD1 | P21728 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 4/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7095067 | 0.86 | HRH1 (0.41) | SETD7ADRA1ACHRM2CHRM1KCNH2 | |
| SCHEMBL15773559 | 0.82 | SETD7 (0.54) | SETD7ADRA1ACHRM2CHRM1KCNH2 | |
| SCHEMBL7095204 | 0.82 | HRH1 (0.62) | CHRM2KCNH2HTR2AHTR2BHRH1 | |
| Alcaftadine SCHEMBL1602418 | 0.81 | SETD7 (0.52) | SETD7ADRA1ACHRM2CHRM1KCNH2 | |
| SCHEMBL5060512 | 0.81 | SETD7 (0.52) | SETD7ADRA1ACHRM2CHRM1KCNH2 | |
| SCHEMBL15790814 | 0.81 | SETD7 (0.52) | SETD7ADRA1ACHRM2CHRM1KCNH2 | |
| Alcaftadine SCHEMBL29378093 | 0.81 | SETD7 (0.52) | SETD7ADRA1ACHRM2CHRM1KCNH2 | |
| SCHEMBL2604746 | 0.81 | SETD7 (0.51) | SETD7ADRA1ACHRM2CHRM1KCNH2 | |
| SCHEMBL2116710 | 0.81 | SETD7 (0.51) | SETD7ADRA1ACHRM2CHRM1KCNH2 | |
| SCHEMBL27300170 | 0.78 | SETD7 (0.48) | SETD7ADRA1ACHRM2CHRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888352-B1 | FUSED IMIDAZOLE DERIVATIVES AS MULTIDRUG RESISTANCE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2003-05-28 | — | — | EP | disclosed |
| US-20030087895-A1 | Fused imidazole derivatives as multidrug resistance modulators | JANSSENS FRANS EDUARD (BE) | 2003-05-08 | — | — | US | disclosed |
| US-6544979-B1 | Having multidrug resistance modulating properties | JANSSEN PHARMACEUTICALS, N.V. (BE) | 2003-04-08 | — | — | US | disclosed |
| EP-1011726-B1 | FUSED IMIDAZOLE DERIVATIVES FOR IMPROVING ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2003-02-26 | — | — | EP | disclosed |
| US-6476018-B1 | Fused imidazole derivatives as multidrug resistance modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-11-05 | — | — | US | disclosed |
| US-6218381-B1 | FOR DECREASING, ELIMINATING OR REVERSING A DEVELOPING OR EXISTING RESISTANCE TO CHEMOTHERAPEUTIC DRUG THERAPY | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-04-17 | — | — | US | disclosed |
| EP-0888352-A1 | FUSED IMIDAZOLE DERIVATIVES AS MULTIDRUG RESISTANCE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034897-A1 | FUSED IMIDAZOLE DERIVATIVES AS MULTIDRUG RESISTANCE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087895-A1 | Fused imidazole derivatives as multidrug resistance modulators | ABCC1, CBR1, ABCB11 | SETD7 931/4885ADRA1A 455/4885CHRM2 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.